Glura M 500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The synergistic action of these agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or those requiring combination therapy. Glura M 500 is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and exercise. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Glura M 500 Tablet should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.